1. A class action lawsuit filed against Biohaven Ltd. for securities fraud. 2. Investors allege significant overstatements about BHVN's drug efficacy and regulatory prospects. 3. The lead plaintiff deadline for participation is September 12, 2025. 4. Misleading statements may negatively impact BHVN's financial outlook. 5. Investors with losses can participate in the lawsuit for potential recovery.
The significant allegations of securities fraud could damage investor trust and stock value. Past cases like Valeant Pharmaceuticals saw drastic stock declines following similar lawsuits.
The lawsuit pertains directly to BHVN's credibility and stock value, warranting high importance. This event could be a central concern for current and prospective investors.
Immediate legal developments and investor sentiment could impact stock price quickly. Previous class action linked declines within weeks after announcements.
BENSALEM, Pa., Aug. 15, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Biohaven Ltd. ("Biohaven" or the "Company") (NYSE: BHVN).
IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN BIOHAVEN LTD. (BHVN), CONTACT THE LAW OFFICES OF HOWARD G. SMITH BEFORE SEPTEMBER 12, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.
Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@howardsmithlaw.com, by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com.
What Is The Lawsuit About?
The complaint filed alleges that, between March 24, 2023 and May 14, 2025, Defendants failed to disclose to investors that: (1) troriluzole's regulatory prospects as a treatment for SCA, and/or the sufficiency of data that Biohaven submitted in support of troriluzole's regulatory approval for this indication, were overstated; (2) BHV-7000's efficacy and clinical prospects as a treatment for bipolar disorder were likewise overstated; (3) all the foregoing, once revealed, was likely to have a significant negative impact on Biohaven's business and financial condition; and (4) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
Contact Us To Participate or Learn More:
If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact:
Howard G. Smith, Esq.,
Law Offices of Howard G. Smith,
3070 Bristol Pike, Suite 112,
Bensalem, Pennsylvania 19020,
Call us at: (215) 638-4847
Email us at: howardsmith@howardsmithlaw.com,
Visit our website at: www.howardsmithlaw.com.
To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contact Us:
Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com
View original content:https://www.prnewswire.com/news-releases/biohaven-ltd-bhvn-investors-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-302531228.html
SOURCE Law Offices of Howard G. Smith